Lupin Ltd (LUPN)

Currency in INR
2,278.90
-21.10(-0.92%)
Closed·
Advertisement
LUPN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2,258.602,288.20
52 wk Range
1,875.002,529.50
Key Statistics
Bid/Ask
2,344.80 / 2,278.90
Prev. Close
2,300
Open
2,285
Day's Range
2,258.6-2,288.2
52 wk Range
1,875-2,529.5
Volume
1.3M
Average Volume (3m)
1.03M
1-Year Change
17.1791%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LUPN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low P/E ratio relative to near-term earnings growth

Lupin Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Lupin Ltd Earnings Call Summary for Q1/2027

  • Lupin posted record Q1 revenue of ₹82.77B (+32% YoY), beating estimates by 5.39%, but missed EPS forecast at 28.7 vs 29.24 expected (-1.85%).
  • EBITDA margin expanded to 30% from 26.6% YoY driven by improved product mix and cost controls; gross margin rose 330 bps to 74.6%.
  • Management expects U.S. revenue pressure at $250M-$280M quarterly near-term before fiscal 2028 recovery; reiterated FY27 high single-digit growth guidance.
  • Company outlined robust pipeline including pegfilgrastim biosimilar, apixaban 505(b)(2) launch (Sept 2027), and multiple injectables to drive long-term growth.
  • Stock declined 0.9% to $2,363.5 in pre-market as investors weighed strong revenue performance against earnings miss and softer U.S. outlook ahead.
Last Updated: 07/08/2026, 13:18
Read Full Transcript

Earnings

Latest Release
05/08/2026
EPS / Forecast
31.00 / 29.24
Revenue / Forecast
82.77B / 78.54B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 120.71%
Dividend Yield
0.78%
Industry Median 0.66%
Annualised payout
18.00
Paid unevenly
5-Years Growth
+22.59%
Growth Streak

Lupin (LUPN) Income Statement & Profits

Compare LUPN to Peers and Sector

Metrics to compare
LUPN
Peers
Sector
Relationship
P/E Ratio
18.7x29.8x−0.4x
PEG Ratio
0.381.620.00
Price/Book
4.6x5.0x2.6x
Price / LTM Sales
3.5x4.5x3.1x
Upside (Analyst Target)
13.4%8.7%48.2%
Fair Value Upside
Unlock1.6%5.8%Unlock

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It produces, develops, and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company also offers products in the therapeutic areas of cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, anti-TB, cephalosporins, and nonsteroidal anti-inflammatory drug therapies. In addition, it provides chronic therapies, and hospital-based products; products for diabetes and iron supplements for anemia, and a Budesonide-Formoterol combination for asthma. Further, the company is involved in the provision of diagnostics services, and digital healthcare services; and neuro rehabilition business. It operates through network consisting of labs and collection centers. The company has a strategic collaboration with TB Alliance to support the clinical development and commercialization of Telacebec for the treatment of tuberculosis, leprosy, and buruli ulcer. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

Employees
26021
Market
India

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
121.65M26.61%279.80B
Other Institutional Investors
261.67M57.23%601.84B
Public Companies & Retail Investors
73.91M16.17%170.00B
Total
457.24M100.00%1.05T

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Lupin Investments Pvt. Ltd.45.31%207,194,390476,547,097
HDFC Asset Management Company Limited6.53%29,841,86268,636,283

People Also Watch

1,658.00
ARBN
+0.61%
354.55
FED
-1.06%
275.00
VDAN
-3.05%
403.00
BHEL
-1.47%
586.65
HZNC
-1.43%

FAQ

What Is the Lupin (NSE: LUPN) Share Price Today?

The Lupin stock price today is 2,278.90 INR.

What Stock Exchange Does Lupin (LUPN) Trade On?

Lupin is listed and trades on the India National Stock Exchange.

What Is the Ticker (Stock Symbol) for Lupin?

The stock symbol (also called a 'ticker') for Lupin is "LUPN."

Does Lupin Pay Dividends? What’s The Current LUPN Dividend Yield?

Yes, LUPN Pays Dividends to its Shareholders. The current Lupin dividend yield is 0.79%.

What Is the Current Lupin Market Capitalisation?

As of today, Lupin (NSE: LUPN) market cap is 1.04T INR.

What Is Lupin's (LUPN) Earnings Per Share (TTM)?

The Lupin EPS is currently 120.71 (Trailing Twelve Months).

When Is the Next Lupin Earnings Date?

Lupin's next earnings report will be released on 11/11/2026.

Is LUPN a Buy or Sell From a Technical Analyst Perspective?

Based on today's Lupin moving averages and other technical indicators, the daily buy/sell signal for LUPN stock is Strong Sell.

How Many Times Has Lupin Stock Split?

Lupin has split 2 times. (See the LUPN stock split history page for full effective split date and price information.)

How Many Employees Does Lupin Have?

Lupin has 26021 employees, based on their latest Companies House report.

What is the current trading status of Lupin (NSE: LUPN)?

As of 11/08/2026, Lupin (LUPN) is trading at a share price of 2,278.90 INR, with a previous close of 2,300.00 INR. The stock has fluctuated within a day range of 2,258.60 INR to 2,288.20 INR, while its 52-week range spans from 1,875.00 INR to 2,529.50 INR.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.